Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The treatment showed consistent effectiveness regardless of folate receptor alpha expression levels or prior PARP inhibitor exposure, a group typically with poor outcomes. Sofe-M is currently being evaluated in multiple Phase 3 trials under the FRAmework-01 program for both platinum-sensitive and platinum-resistant ovarian cancer. These results suggest a promising new treatment option for ovarian cancer patients with limited alternatives.
Following Eli Lilly's promising clinical data announcement for its ovarian cancer drug Sofe-M, the company's stock on Pluang is trading at USD 1,273.46 as of Oct 24, 2026 13:41 WIB. Despite the positive news, LLY shares have seen a 2.54% decline in the past day, with a market cap of $1.16 trillion. Investor activity on Pluang shows a majority leaning towards selling, with 76% of orders as of the same time.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
